A phase II randomized trial comparing radiation doses in concurrent chemoradiotherapy with TS-1/nedaplatin for curative treatment of newly diagnosed or recurrent esophageal cancer.

2026-07-31

Hideomi Yamashita *

Subaru Sawayanagi

Mei Kono

Tomoki Kiritoshi

Kosuke Morishima

Haruka Jinnouchi

Yuki Nozawa

Atsuto Katano

DOI：10.1016/j.ijrobp.2026.07.019

Original

Original request for help

Save

Abstract

En 中文

To evaluate and compare progression-free survival (PFS) between 50.4-Gy and 60-Gy radiation doses in definitive chemoradiotherapy (CRT) for patients with esophageal cancer, and to confirm that the 50.4-Gy is non-inferior to the 60-Gy irradiation method in terms of PFS.

Keywords:

esophageal cancer

radiotherapy

and radiation dose comparison

A phase II randomized trial comparing radiation doses in concurrent chemoradiotherapy with TS-1/nedaplatin for curative treatment of newly diagnosed or recurrent esophageal cancer.

Abstract

Journal

Organization

Cited Papers

Citing Papers